ANGPT2 and cancer: The SPR results demonstrated that the Ang2-BD bi-specific variants could bind other integrins that are overexpressed in cancer and in the tumor vasculature, such as αvβ5 and α5β1 integrins, but do not bind to other integrins (such as α3β1, αIIbβ3, and α4β7) that are less dominantly expressed in cancer and the tumor vasculature.